Deflazacort NDC 59651-601

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-601Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0601Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-601-30	59651060130	30 TABLET in 1 BOTTLE (59651-601-30)Marketed from Feb 9, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deflazacort
Generic name (nonproprietary): deflazacort
Active ingredients: Deflazacort — 30 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 217123
Marketing start: Feb 9, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 59651-601_a6a915ee-9df8-46ee-a6b7-794834417917SPL ID a6a915ee-9df8-46ee-a6b7-794834417917SPL set ID 77d7525d-89c9-4fde-a6a8-0a463fd6cfebRxCUI 153098, 153880, 1870954, 1870958UNII KR5YZ6AE4BUPC 0359651600306
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651060130 followed by a unit qualifier and the quantity

Package 59651-0601-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 1, 2026.

Indications (excerpt from the label)

Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 217123

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 217123
Product	Strength	Form · route	Labeler	Product NDC
Deflazacort	Deflazacort 18 mg/1	TabletOral	Aurobindo Pharma Limited	59651-600
Deflazacort	Deflazacort 6 mg/1	TabletOral	Aurobindo Pharma Limited	59651-599
Deflazacort	Deflazacort 36 mg/1	TabletOral	Aurobindo Pharma Limited	59651-602